Pharming Group (NASDAQ:PHAR) Shares Gap Down – Time to Sell?

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) gapped down prior to trading on Friday . The stock had previously closed at $14.81, but opened at $14.13. Pharming Group shares last traded at $13.69, with a volume of 8,287 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Zacks Research downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 30th. Weiss Ratings upgraded shares of Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.00.

Pharming Group Price Performance

The stock’s fifty day moving average price is $14.27 and its 200-day moving average price is $11.62. The firm has a market cap of $931.74 million, a price-to-earnings ratio of -104.62 and a beta of 0.04. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The business had revenue of $93.20 million during the quarter, compared to the consensus estimate of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC bought a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 2,979 shares of the company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.